

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number
WO 01/38587 A2

(51) International Patent Classification⁷: C12Q 1/68 (74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 et al. (US).

(21) International Application Number: PCT/US00/32536 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 29 November 2000 (29.11.2000) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/167,940 29 November 1999 (29.11.1999) US

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FURFINE, Eric, Steven [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). PORTER, David, John, Timothy [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). ROBERTS, Grace, Brashears [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

(54) Title: CONTINUOUS TIME-RESOLVED RESONANCE ENERGY-TRANSFER ASSAY FOR POLYNUCLEIC ACID POLYMERASES

WO 01/38587

(57) Abstract: A method of detecting polynucleic acid polymerase activity, including DNA and RNA polymerase activity. The method includes providing a polynucleic acid primer-template complex labeled with a energy-emitting chemical species and a nucleotide labeled with a energy-emitting chemical species; mixing the polynucleic acid primer-template complex and the nucleotide with a sample comprising or suspected to comprise a polynucleic acid polymerase; prior to, contemporaneously with or after the mixing, exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the energy-emitting chemical species to thereby excite that energy-emitting chemical species; and detecting a signal produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase, the detection of the signal indicating polynucleic acid polymerase activity in the sample. Candidate compounds can also be identified as modulators of polynucleic acid polymerase activity via the method.

DescriptionCONTINUOUS TIME-RESOLVED RESONANCE ENERGY-TRANSFER
ASSAY FOR POLYNUCLEIC ACID POLYMERASES

5

Cross Reference to Related Applications

This application is based on and claims priority to U.S. provisional patent application serial no. 60/167,940, filed November 29, 1999, herein incorporated by reference in its entirety.

10

Technical Field

The present invention pertains generally to methods of detecting polynucleic acid polymerase activity. More particularly, the present invention pertains to a continuous assay method for detecting polynucleic acid polymerase activity over a predetermined time period and to an assay method for identifying a candidate compound as a modulator of polynucleic acid polymerase activity.

Table of Abbreviations

20	AIDS	-	acquired immune deficiency syndrome
	CY2	-	a commercially available fluorescent dye
	CY3	-	a commercially available fluorescent dye
	CY5	-	a commercially available fluorescent dye
	CY7	-	a commercially available fluorescent dye
25	DEPC	-	diethyl pyrocarbonate
	DMSO	-	dimethyl sulfoxide
	DTT	-	dithiothreitol
	em	-	emission wavelength
	ex	-	excitation wavelength
30	HIV	-	human immunodeficiency virus
	HTRF	-	homogeneous time-resolved fluorescence

-2-

	[I]	-	inhibitor concentration (units: M)
	IC ₅₀	-	concentration in M of modulator which there is 50% modulation of polynucleic acid polymerase activity -- the lower the IC ₅₀ is, then the more potent the modulator is
5			
	infrared 40	-	a commercially available fluorescent dye
	IRD 40	-	a commercially available fluorescent dye
10	k _{on}	-	on rate constant for modulator binding to polynucleic acid polymerase (units: M ⁻¹ min ⁻¹)
	k _{off}	-	off rate constant for modulator dissociation from modulator-polynucleic acid polymerase complex (units: min ⁻¹)
15	M	-	molarity (units: moles/liter)
	MR 200	-	a commercially available fluorescent dye
	NNRTI	-	non-nucleoside reverse transcriptase inhibitor
	NP40	-	Nonidet-P40
20	RT	-	reverse transcriptase
	SPA	-	scintillation proximity assay
	V _{max}	-	uninhibited reaction rate
	WT	-	wild type

25

Background Art

Polynucleic acid polymerases, including DNA and RNA polymerases, catalyze the incorporation of nucleotides onto template strands of polynucleic acids *in vivo*. These polymerases thus play important roles in the synthesis of new DNA molecules and in the synthesis of RNA molecules 30 for subsequent translation into functional and structural proteins.

-3-

A polynucleic acid polymerase of particular interest is the reverse transcriptase encoded by the human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency syndrome (AIDS). Reverse transcriptase (RT) is essential to viral replication and proliferation. The 5 polymerase is called reverse transcriptase because it catalyzes the synthesis of DNA molecules from the RNA molecules carried by HIV. Thus, this polynucleic acid polymerase, as well as other polynucleic acid polymerases, has been the target of substantial research efforts for modulators of their biological activity, including particularly inhibitors of their 10 biological activity.

For example, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been identified and are effective in treating AIDS when combined with nucleoside RT inhibitors and HIV protease inhibitors. See Artico, M. (1996), *Farmaco* 51:305-331; DeClerk, E. (1996), *Medical Virology* 15 6:97-117. However, many NNRTIs are slow-binding inhibitors of wild type RT. Determining true affinities of inhibitors requires monitoring the time-course of enzymatic activity. Current methods for measuring RT activity are typically based on radioactive endpoint assays. In such assays, multiple reaction wells that each represent a single time-point must be employed. 20 Thus, monitoring the time-course is a relatively tedious process. Additionally, because many NNRTIs are slow, time-dependent inhibitors of wild type RT, IC₅₀ values determined by conventional endpoint assay methods can be erroneously high.

RT scintillation proximity assay (SPA) currently available from 25 Amersham Life Science, Piscataway, New Jersey detects incorporation of (³H)-TMP into a primer-template complex via streptavidin-coated SPA bead that is attached to a 5'-biotin on the primer. The beads must be added to the sample at the end of the reaction because RT cannot efficiently catalyze primer extension in the presence of the beads. Thus, this assay is also 30 effectively an endpoint assay.

-4-

What is needed, then, is an assay to monitor the time-course of RT or other polynucleic acid polymerase modulation by NNRTIs or by other candidate modulator compounds. Such an assay would facilitate determination of whether a modulator binds a polynucleic acid polymerase 5 rapidly or slowly; would facilitate calculation of accurate IC₅₀ values; and would allow for relevant comparison of modulation potency between candidate modulators. Such an assay is not currently available in the art.

Summary of the Invention

10 A method of detecting polynucleic acid polymerase activity is disclosed. The method comprises providing a polynucleic acid primer-template complex labeled with an energy-emitting chemical species and a nucleotide labeled with an energy-emitting chemical species; mixing the polynucleic acid primer-template complex and the nucleotide with a sample 15 comprising or suspected to comprise a polynucleic acid polymerase; prior to, contemporaneously with or after the mixing, exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the energy-emitting chemical species to thereby excite that energy-emitting chemical species; and 20 detecting a signal produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase, the detection of the signal indicating polynucleic acid polymerase activity in the 25 sample.

A method for identifying a candidate compound as a modulator of polynucleic acid polymerase activity is also disclosed. The method comprises providing a candidate compound, a polynucleic acid primer-template complex labeled with an energy-emitting chemical species and a 30 nucleotide labeled with an energy-emitting chemical species; mixing the candidate compound, the polynucleic acid primer-template complex and the

-5-

nucleotide with a polynucleic acid polymerase; prior to, contemporaneously with or after the mixing, exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the energy-emitting chemical species to thereby excite 5 that energy-emitting chemical species; detecting a signal produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity 10 of the polynucleic acid polymerase, the detected signal indicating an amount of polynucleic acid polymerase activity; and identifying the candidate compound as a modulator of polynucleic acid polymerase activity based on the amount of signal detected as compared to a control sample.

Accordingly, it is an object of the present invention to provide a novel assay for polynucleic acid polymerase activity. The object is achieved in 15 whole or in part by the present invention.

An object of the invention having been stated hereinabove, other objects will become evident as the description proceeds when taken in connection with the accompanying Laboratory Examples as best described herein below.

20

Detailed Description of the Invention

The present invention pertains to a continuous assay for polynucleic polymerase activity that monitors polynucleic acid primer extension based on time-resolved resonance energy transfer, and preferably time-resolved 25 fluorescence energy transfer. The terms "continuous" or "kinetic" are meant to refer to the detection of a signal at a plurality of time points in a single reaction. The present invention thus represents a novel application of the resonance energy transfer that occurs when energy from an excited donor energy-emitting chemical species (e.g. a fluorophore) is transferred directly 30 to an acceptor energy-emitting chemical species (e.g. a fluorophore) in a continuous or kinetic assay for polynucleic acid polymerase activity.

-6-

Following long-standing patent law convention, the terms "a" and "an" mean "one or more" when used in this application, including the claims.

Time-resolved, or time-gated fluorescence spectroscopy is described in U.S. Patent Nos. 4,058,732 and 4,374,120, incorporated by reference herein. This technique employs a fluorescent probe that has a fluorescence decay (lifetime) that substantially exceeds the duration of the exciting pulse and the duration of the background non-specific fluorescence. A time-gating is used to reduce the background fluorescence, i.e., the measurement of the fluorescence is delayed until a certain time has elapsed from the moment of excitation. The delay time is sufficiently long for the background fluorescence to have ceased. When the fluorescence signal is measured (after the delay) the measurement is an integrated measurement, i.e. all the light arriving at the detector during the measuring period is measured without regard to the time of arrival. The purpose of this delayed measurement is to ensure that only one fluorescence signal reaches the detector during measurement.

In accordance with the present invention, a method of detecting polynucleic acid polymerase activity is provided. In the method, a polynucleic acid primer-template complex labeled with an energy-emitting chemical species is provided. Nucleotides labeled with an energy-emitting chemical species are also provided. The polynucleic acid primer-template complex and the nucleotides are mixed in the presence or suspected presence of a polynucleic acid polymerase. Prior to, in conjunction with or after this mixing, the labeled polynucleic acid primer-template complex and the labeled nucleotide are exposed to radiation of excitation wavelength (e.g. with a light pulse) for one of the energy emitting chemical species to thereby excite that energy-emitting chemical species. A signal is produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer of the polynucleic acid primer-template complex (also referred to herein as "primer extension") via the

-7-

activity of the polynucleic acid polymerase. Thus, the detection of the signal indicates the presence of polynucleic acid polymerase activity. Preferably, the signal is detected at a plurality of time points over a predetermined time-period to thereby determine polymerase activity over the predetermined 5 time-period.

The polynucleic acid primer-template complex is prepared by annealing a polynucleic acid primer (e.g. a DNA or an RNA molecule) to a complementary polynucleic acid template (e.g. a DNA or an RNA molecule) under suitable annealing conditions. Representative annealing conditions 10 are provided in the Laboratory Examples herein. Generally, conditions for annealing polynucleic acids are known in the art, see e.g. Sambrook, J., et al., *Molecular Cloning: a Laboratory Manual*, Cold Spring Harbor, New York, New York (1989), incorporated by reference herein. Any desired polynucleic acid primer-template complex can be employed in accordance with the 15 present invention. With the appropriate primer-template complex, the present invention can be used to measure primer extension catalyzed by polynucleic acid polymerases from any organism, including but not limited to, viruses, bacteria (e.g., *E. coli*), plants, or animals (mammals).

The term "nucleotide" is believed to be well-understood in the art and 20 is meant to refer to a phosphate ester of a nucleoside, and preferably, to 5' triphosphate esters of the five major bases of DNA and RNA. The term "nucleotide" therefore includes deoxyribonucleoside triphosphates (dNTP's), e.g. dUTP, dTTP, dATP, dCTP, dGTP, and ribonucleoside triphosphates (NTP's), e.g. ATP, CTP, UTP and GTP. The dNTP's and NTP's can be 25 labeled with an energy-emitting chemical species for use in the method of the present invention. Modified nucleotide bases (e.g. methylated bases) are also contemplated.

Nucleoside triphosphates are substrates for polymerases, and once incorporated, the nucleotide is in the monophosphate form. Thus, the term 30 "nucleotide" as used herein and in the claims is also meant to refer to nucleoside monophosphate molecules. The term "nucleoside

monophosphate" includes deoxyribonucleoside monophosphates (dNMP's), e.g. dUMP, dTMP, dAMP, dCMP, dGMP, and ribonucleoside monophosphates (NMP's), e.g. AMP, CMP, UMP and GMP.

The polynucleic acid primer-template complex and the nucleoside triphosphate molecules are conjugated, bound or otherwise labeled with an energy-emitting chemical species as described herein. As used herein, the terms "label" or "labeled" refers to incorporation of an energy-emitting chemical species, e.g., by incorporation into the polynucleic acid primer-template complex of a nucleotide having biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker). Various other methods of labeling polynucleic acids and nucleotides are known in the art and can also be used.

In accordance with the present invention, the detectable signal is generated from resonant interaction between two energy emitting chemical species: an energy contributing donor chemical species and an energy receiving acceptor chemical species. The polynucleic acid primer-template complex can be labeled with the donor chemical species while the nucleoside triphosphate can be labeled with the acceptor chemical species, and vice versa. Within the polynucleic acid primer-template complex, the polynucleic acid primer can be labeled at its 5' end or the polynucleic acid template can be labeled at its 3' end or its 5' end. In either case, in accordance with the biological activity of polynucleic acid polymerases, the labeled nucleotides are incorporated into the 3' end of the primer to provide the appropriate spatial relationship for resonance energy transfer between the energy-emitting chemical species as disclosed herein. Moreover, in a preferred embodiment of the present invention as disclosed in the Examples presented herein and in accordance with the biological activity of polynucleic acid polymerases, the labeled nucleotide is complementary to the nucleotide base available on the template for primer extension.

The term "energy-emitting chemical species" is believed to be well understood by one of skill in the art and is meant to refer to any chemical

species, whether an atom, molecule, complex or other chemical species, that emits energy in response to a stimulus. The methods of the present invention are contemplated to be useful for any combinations of energy-emitting chemical species so long as the emitted energy from one chemical species is sufficiently intense so as to produce as an energy emission from the other chemical species in accordance with the present invention. For example, energy transfer can occur when the emission spectrum of the donor overlaps the absorption spectrum of the acceptor. Thus, in a preferred embodiment of the present invention, acceptor and donor chemical species are chosen and paired together based on these characteristics. Also, the donor and the acceptor must be within a certain distance, i.e. preferably within the same polynucleic acid primer-template complex, from each other.

Preferred "energy-emitting chemical species" comprise luminescent or light emitting molecules, such as fluorescent, phosphorescent, and chemiluminescent molecules, which emit light when excited by excitation light. Preferred donor/acceptor combinations that can be used in the present inventive method are fluorescent donors with fluorescent or phosphorescent acceptors, or phosphorescent donors with phosphorescent or fluorescent acceptors.

Fluorescent compounds can thus be used to label the polynucleic primer-template complexes and nucleotides employed in the methods of the present invention. Representative fluorescent labeling compounds include dinitrophenyl, fluorescein and derivatives thereof (such as fluorescein isothiocyanate), rhodamine, derivatives of rhodamine (such as methylrhodamine and tetramethylrhodamine), phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. Representative fluorescent dyes include Texas red, Rhodamine green, Oregon green, Cascade blue, phycoerythrin, CY3, CY5, CY2, CY7, coumarin, infrared 40, MR 200, and IRD 40. Representative chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole,

-10-

acridinium salt and oxalate ester, while representative bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin. All of the compounds are available from commercial sources, such as Molecular Probes, Inc., Eugene, Oregon and Sigma Chemical Company, St.

5 Louis, Missouri.

Representative commercially available fluorescent labeled dNTP include fluorescein-dUTP, fluorescein-dATP (Boehringer Mannheim, Indianapolis, Indiana; Pharmacia Biosystems Aktiebolaget, Uppsala, Sweden); Texas red-dCTP and dGTP (NEN-Dupont, Wilmington, Delaware),
10 FLUOROLINK™ CY5-dCTP and dUTP as well as FLUOROLINK™ CY3-dCTP and dUTP (Pharmacia Biosystems Aktiebolaget, Uppsala, Sweden) and the labeled dUTP's and UTP's sold under the trademarks ALEXA™ and BIODPY® by Molecular Probes, Inc., Eugene, Oregon.

The energy-emitting chemical species can comprise any of the
15 fluorescent rare earth metals. Preferably, the fluorescent rare earth metal is of the Lanthanide Series (elements 57-70 of the periodic table). The Lanthanide Series comprises lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er),
20 thulium (Tm), ytterbium (Yb) and lutetium (Lu).

The use of lanthanides is preferred, and the use of lanthanide chelates is more preferred, in view of the long lived fluorescence of lanthanide elements, compared to ordinary fluorescent backgrounds which otherwise tend to overwhelm a genuine signal. For example, the trivalent
25 lanthanide ions Eu³⁺, Tb³⁺, and Sm³⁺ all have fluorescent decay times on the order of milliseconds compared to nanosecond decay times for background fluorescence. By irradiating a reaction sample at the appropriate wavelength and energy level, the fluorescence can be measured at a delayed point in time, after background fluorescence has already decayed, but while the
30 lanthanide specimen is still emitting to facilitate detection of polymerase activity via time-resolved fluorescence spectroscopy.

-11-

Thus, in a preferred embodiment of the continuous assay of the present invention, a polynucleic acid polymerase catalyzes the incorporation of a deoxyuridine monophosphate (dUMP) or uridine monophosphate (UMP) analog labeled with a fluorescent dye into a lanthanide chelate-labeled 5 primer-template complex. Primer extension is monitored by the fluorescence energy transfer from the lanthanide to incorporated labeled-dUMP or -UMP.

In a more preferred embodiment of the present invention, RT catalyzes the incorporation of a deoxyuridine monophosphate (dUMP) 10 analog labeled with CY5 dye into a europium (Eu)-labeled primer-template complex. Incorporation of CY5-dUMP into the Eu-primer-template complex is monitored by the fluorescence energy transfer from Eu (excitation 340 nm, emission 620 nm) to CY5-dUMP (excitation 649 nm, emission 670 nm). The signal amplitude change is linearly dependent on enzyme concentration and 15 time.

A method for identifying a candidate compound having an ability to modulate polynucleic acid polymerase activity is also disclosed. A polynucleic acid primer-template complex labeled with an energy-emitting chemical species is provided, as is a nucleoside triphosphate labeled with an 20 energy-emitting chemical species. The candidate compound, the polynucleic acid primer-template complex and the nucleoside triphosphate are then mixed. Prior to, contemporaneously with or after mixing, the labeled polynucleic acid primer-template and the labeled nucleoside triphosphate are exposed to radiation of excitation wavelength (e.g. with a 25 light pulse) for one of the energy emitting chemical species to thereby excite that chemical species.

Prior to, contemporaneously with or after the exposure, a polynucleic acid polymerase is added to the mixture. The production of a signal, e.g. a fluorescence signal, is detected, preferably at a plurality of time points over a 30 predetermined time-period. By a "predetermined time-period", it is meant any suitable time-period over which the time-course of modulation of a

-12-

polynucleic acid polymerase by a candidate compound can be established. A representative 40 minute time-period is used to establish the time-courses for RT inhibition by candidate compounds in the Laboratory Examples below.

5 The signal is produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase. The candidate compound is identified as a modulator of polynucleic acid 10 polymerase activity based on modulation of signal amplitude in the predetermined time-period relative to a control sample.

The method can further comprise determining whether a candidate modulator compound binds the polynucleic acid polymerase rapidly or slowly. Steady-state IC₅₀ values for the candidate modulator compound can 15 also be calculated, thus further providing a relevant comparison of the modulation potency between compounds. The term "candidate compound" or "candidate substrate" is meant to refer to any compound wherein the characterization of the compound's ability to modulate polynucleic acid polymerase activity is desirable. "Modulate" is intended to mean an 20 increase, decrease, or other alteration of any or all biological activities or properties of a polynucleic acid polymerase. Exemplary candidate compounds or substrates include xenobiotics such as drugs and other therapeutic agents, as well as endobiotics such as steroids, fatty acids and prostaglandins. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), 25 which have been shown to be effective in treating AIDS when combined with nucleoside RT inhibitors and HIV protease inhibitors (see Artico, M. (1996), *Farmaco* 51:305-331; DeClerk, E. (1996), *Medical Virology* 6:97-117, incorporated by reference herein), are particularly contemplated candidate compounds, as are nucleoside analogs.

30 Because many NNRTIs are slow time-dependent inhibitors of wild type (WT) RT, IC₅₀ values determined by conventional endpoint assays for

-13-

the identification of NNRTI inhibitors can be erroneously high. Thus, in a preferred embodiment of the present invention, the time-course of RT inhibition by NNRTIs is monitored. With the assay method of the present invention, one can determine whether an inhibitor binds RT rapidly or slowly.

5 Steady-state IC_{50} values can be calculated from these data and the appropriate model, thus providing a relevant comparison of the inhibition potency between compounds.

The determination of steady-state IC_{50} values for nevirapine, delavirdine, and efavirenz (commercially available compounds currently 10 marketed as NNRTI's) with wild-type RT and 11 NNRTI-resistant mutants is disclosed in the Laboratory Examples. Association and dissociation rate constants were determined for the slow binding inhibitors. Decreased sensitivity to the NNRTIs was associated with increased values of dissociation rate constants.

15 As also disclosed in the Laboratory Examples, the method of the present invention can be performed within standard multi-well assay plates as are well known in the art, such as 96-well or 384-well micro-titer plates. Thus, a plurality of candidate compounds can be simultaneously screened 20 for an ability to modulate polynucleic acid polymerase activity within multiple wells of a multi-well plate or via multiple samples on a suitable substrate to provide for high throughput screening of samples in accordance with the present invention. Thus, the present invention provides a polynucleic acid polymerase activity assay that allows for the monitoring of the time-course of 25 the primer extension reaction in a single tube or well, rather than in multiple wells that each represent a single time point, to thereby facilitate the obtaining of kinetic data and the analysis of modulator binding characteristics.

30 Summarily, the assay method of the present invention simplifies and quickens the kinetic analysis of modulator binding, and allows for the determination of values for association and dissociation rate constants. The primer-template complex can be modified to determine modulation (e.g.

-14-

inhibitory) constants for nucleoside analogs as well as non-nucleoside polymerase inhibitors. Indeed, the assay method of the present invention has been used to determine steady-state IC₅₀ values for non-nucleoside HIV reverse transcriptase inhibitors, as disclosed in the Laboratory Examples.

5

Laboratory Examples

The following Laboratory Examples have been included to illustrate preferred modes of the invention. Certain aspects of the following Laboratory Examples are described in terms of techniques and procedures found or contemplated by the present inventors to work well in the practice of the invention. These Laboratory Examples are exemplified through the use of standard laboratory practices of the inventors. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Laboratory Examples are intended to be exemplary only and that numerous changes, modifications and alterations can be employed without departing from the spirit and scope of the invention.

Materials and Methods Used in Laboratory Example 1

Expression and purification: DNA encoding wild type and mutant HIV-1 reverse transcriptase (RT) was cloned, expressed and purified by standard techniques, such as those described in Ausubel et al., *Current Protocols in Molecular Biology*, (J. Wiley & Sons, N.Y.)(1992); Adelman, et al. *DNA* 2:183 (1983); and Messing et al. *Third Cleveland Symposium on Macromolecules and Recombinant DNA*, Editor A. Walton, Elsevier, Amsterdam (1981), herein incorporated by reference. Table 1 shows the peptide sequence for wild type RT. The residues (L100->I, K103->N, V106->A, V106->I, V108->I, E138->K, Y181->C, Y188->C, and P236->L) that were mutagenized via conventional site-specific mutagenesis techniques are indicated in bold in the peptide sequence. Table 2 indicates the amino acid changes for each mutant RT.

Table 1
Polypeptide Sequence for Wild-Type RT Polypeptide (SEQ ID NO:1)

1	PISPIETVPV	KLKPGMDGPK	VKQWPPLTEEK	IKALVEICTE	MEKEGKISKI
51	GPNPYNTPV	FAIKKKDSTK	WRKLVDFREL	NKRTQDFWEV	QLGIPHPAGL ¹⁰⁰
101	KKK ¹⁰³ KSV ¹⁰⁶ TV ¹⁰⁸ LD	VGDAYFSVPL	DEDFRKYTAF	TIPSINNE ¹³⁸ TP	GIRYQYNIVLP
141	QGWKGSPAIF	QSSMTKILEP	FRKQNPDIVI	Y ¹⁸¹ QYMDDLY ¹⁸⁸ VG	SDLEIGQHRT
191	KIEELRQHLL	RWGLLTPDKK	HQKEPPFLWM	GYELHP ²³⁶ DKWT	VQPIVLPEKD
241	SWTVNDIQKL	VGKLNWASQI	YPGIKVVRQLC	KLLRGTKALT	EVIPLTEEAE
291	LELAENREIL	KEPVHGVYYD	PSKDLIAEIQ	KQGQQGQWTYQ	IYQEPEFKNLK
341	TGKYARMRGA	HTNDVKQLTE	AVQKITTESI	VIWGKTPKFK	LPIQKETWET
391	WWTEYWQATW	IPWEWFVNTP	PLVKLWYQLE	KEPIVGAETF	YVDGAANRET
441	KLGKAGYVTN	RGRQKVVTLT	DTTNQKTELQ	AIYLAQDSG	LEVNIVTDSQ
491	YALGIIQAAQP	DQSESELVNQ	IIEQLIKKEK	VYLAWVPAHK	GIGGNEQVDK
551	LVSAGIRKVVL				

-16-

Table 2
RT's Screened In Laboratory Examples

RT sub type
WT
L100I
K103N
V106A
V106I
V108I
E138K
Y181C
Y188C
P236L
Y181C/V106A
Y181C/V108I

Biotinylated Template Primer (25:17mer): All buffers were made with diethyl pyrocarbonate (DEPC)-treated water and autoclaved. Template primer was made in sterile RNase-free containers. 5'-biotinylated DNA primer, biotin-5'-GTC ATA GCT GTT TCC TG-3' (SEQ ID NO:2), and the RNA template, 5'-AUU UCA CAC AGG AAA CAG CUA UGA C-3' (SEQ ID NO:3), were custom synthesized by Oligos Etc., Wilsonville, Oregon. The 5'-biotinylated 17-mer DNA primer (40 nmoles) was mixed with the 25-mer RNA template (20 nmoles) in 1 ml of 10 mM Tris-HCl, pH 8.0, 1 mM MgCl₂.

-17-

The solution was divided into 9 x 111 μ l samples, heated in a dry bath incubator (Fisher Scientific, Pittsburgh, Pennsylvania) at 92°C for 5 min., cooled to 40°C over 4 hrs, and stored at -20°C.

Substrate, Enzyme, and Test Compound Solution Preparation:

5 Substrate solution and diluted RT were prepared on the day of the assay and stored on ice. Test compounds (100 μ M in DMSO in column 1 of a 96-well polypropylene plate) were serially diluted 2-fold into DMSO in column 2 through column 11 of the plate using a BIOMEK® 2000 (Beckman Instruments, Fullerton, California). Column 12 of the plate contained only 10 DMSO. The DMSO solutions (10 μ l) were then diluted with 140 μ l H₂O using a RAPIDPLATE® 96-well pipetting station (Zymark Corporation, Hopkinton, Massachusetts).

Reagents and Labware.

96 well plates: Polypropylene for intermediate dilutions (Costar, 15 Oneonta, New York, catalog #3794) and black round-bottom plates (Dynex Technologies, Chantilly, Virginia, catalog #7205) for assays.

Assay Buffer: 66.7 mM Tris-HCl, pH 8, 107 mM KCl, 13.3 mM MgCl₂, 0.0043% NP40, 13.3 mM DTT.

Cy5-AP3-dUTP: Amersham Life Science, Arlington Heights, Illinois, 20 Cat. No. PA55022.

Eu-labeled Streptavidin: Wallac, Gaithersburg, Maryland, #CR28-100.

RT: (diluted to 5 nM in Assay Buffer);

Substrate Solution: 200 nM Cy5-dUTP, 80 nM Eu-labeled 25 Streptavidin, 80 nM biotinylated template primer in Assay Buffer.

Laboratory Example 1 - RT Assay

Reactions contained 100 nM Cy5-dUTP, 40 nM Eu-labeled template-primer complex, 1 nM RT, 47 mM Tris-HCl, 75 mM KCl, 9.3 mM MgCl₂, 30 0.003% NP40, 9.3 mM dithiothreitol (DTT), and 2% dimethyl sulfoxide (DMSO). Test compound or control solvent (15 μ l) was added to each well


-18-

containing 25 μ l of substrate solution. Wells in column 12 contained substrate solution and control solvent without inhibitor and served as uninhibited controls. The Eu chemical species was then excited by exposing the reactions to radiation of excitation wavelength 340 nm with a light pulse.

5 The assay was initiated by adding 10 μ l of diluted RT (wild type RT and RT mutants described above) to each well using a RAPIDPLATE® 96 well pipetting station. The amplitude of the signal was linearly dependent on enzyme concentration and time. Incorporation of Cy5-dUMP into the Eu-labeled template primer (fluorescence energy transfer from Eu (excitation 10 340 nm, emission 620 nm) to cy5-dUMP (excitation 649 nm, emission 670 nm)) was monitored over 40 minutes by time-resolved fluorescence with a VICTOR² -1420™ Multilabel Counter (Wallac, Gaithersburg, Maryland).

Laboratory Example 2 - Data Analysis

15 All data reduction was done with scientific graphing and statistical analysis software sold under the registered trademark SigmaPlot® by Jandel Scientific, Corte Madera, California. Background fluorescence was subtracted from all fluorescence readings. Data analyses were based on the following scheme:



where E' is a mixture of free enzyme, enzyme-nucleotide complex, enzyme-template primer complex, and enzyme-nucleotide-template primer complex, I is inhibitor, k_{on} is the inhibitor on rate constant, k_{off} is the inhibitor off rate constant, V_{max} is the uninhibited reaction rate, and P is the product.

25 If reactions were linear over 40 min, then IC₅₀ values were determined by fitting equation (1):

$$y = V_{max} * IC_{50} * t / (IC_{50} + [I])$$

30

-19-

to the data where y was the observed fluorescence at time t (minutes), V_{max} was the uninhibited rate (fluorescence min^{-1}), and $[I]$ was the inhibitor concentration (molar, or M).

5 If inhibited reactions were not linear over 40 min, indicating slow time-dependent inhibition, values of kinetic constants k_{on} and k_{off} were determined by non-linear least square fit of the equation (2):

$$y = (V_{max} * k_{off} / (k_{on} * [I] + k_{off}) * t) + (V_{max} * k_{on} * [I] / ((k_{on} * [I] + k_{off})^2)) * (1 - \exp(-(k_{on} * [I] + k_{off}) * t))$$

10 where y , V_{max} , and I were defined as above, k_{off} was the off rate constant (min^{-1}), and k_{on} was the on rate constant ($\text{M}^{-1} \text{ min}^{-1}$). The IC_{50} value was determined by equation (3):

$$IC_{50} = k_{off} / k_{on} (M).$$

-20-

Table 3 - Assay Results

RT	nevirapine				delavirdine				efavirenz			
	k_{on} (M ⁻¹ min ⁻¹)	k_{off} (min ⁻¹)	IC_{50} (M)	k_{on} (M ⁻¹ min ⁻¹)	k_{off} (min ⁻¹)	IC_{50} (M)	k_{on} (M ⁻¹ min ⁻¹)	k_{off} (M ⁻¹ min ⁻¹)	IC_{50} (M)	k_{on} (min ⁻¹)	k_{off} (min ⁻¹)	IC_{50} (M)
5	WT	2.94X10 ⁵	5.61X10 ⁻²	1.91X10 ⁻⁷	1.08X10 ⁶	3.78X10 ⁻²	3.50X10 ⁻⁸	1.78X10 ⁷	1.48X10 ⁻²	<3.00X10 ⁻³		
	L100I	na ¹	na	1.51X10 ⁻⁶	na	na	1.70X10 ⁻⁶	2.31X10 ⁷	4.11X10 ⁻¹	1.84X10 ⁻⁶		
	K103N	na	na	1.12X10 ⁻⁵	na	na	.9.12X10 ⁻⁷	na	na	2.85X10 ⁻⁸		
	V106A	na	na	5.01X10 ⁻⁵	1.24X10 ⁶	2.73X10 ⁻¹	2.20X10 ⁻⁷	1.29X10 ⁷	3.45X10 ⁻²	2.66X10 ⁻⁹		
	V106I	nt ²	nt	nt	1.45X10 ⁶	4.78X10 ⁻²	3.30X10 ⁻⁸	1.34X10 ⁷	1.41X10 ⁻²	<3.00X10 ⁻³		
10	V108I	na	na	6.76X10 ⁻⁶	3.34X10 ⁶	1.20X10 ⁻¹	3.59X10 ⁻⁸	1.94X10 ⁷	3.03X10 ⁻²	<3.00X10 ⁻³		
	E138K	1.62X10 ⁵	6.62X10 ⁻²	4.09X10 ⁻⁷	1.27X10 ⁶	3.97X10 ⁻²	3.13X10 ⁻⁸	6.62X10 ⁶	1.35X10 ⁻²	<3.00X10 ⁻³		
	Y181C	na	na	3.47X10 ⁻⁵	na	na	7.59X10 ⁻⁷	8.80X10 ⁶	1.70X10 ⁻²	<3.00X10 ⁻³		
	Y181C/V106A	na	na	>2.00X10 ⁻⁶	na	na	>2.00X10 ⁻⁶	2.35X10 ⁷	1.33X10 ⁻¹	5.63X10 ⁻⁹		
	Y181C/V108I	na	na	>2.00X10 ⁻⁶	na	na	7.59X10 ⁻⁷	2.22X10 ⁷	7.94X10 ⁻²	3.60X10 ⁻⁹		
15	Y188C	na	na	>2.51X10 ⁻⁵	na	na	1.17X10 ⁻⁷	2.66X10 ⁷	2.12X10 ⁻¹	8.01X10 ⁻⁹		

Table 3 - Assay Results (continued)

RT	nevirapine			delavirdine			efavirenz		
	<u>k_{on}</u> (M ⁻¹ min ⁻¹)	<u>k_{off}</u> (min ⁻¹)	<u>IC₅₀</u> (M)	<u>k_{on}</u> (M ⁻¹ min ⁻¹)	<u>k_{off}</u> (M ⁻¹ min ⁻¹)	<u>IC₅₀</u> (M)	<u>k_{on}</u> (M ⁻¹ min ⁻¹)	<u>k_{off}</u> (M ⁻¹ min ⁻¹)	<u>IC₅₀</u> (M)
5 P236L	1.66X10 ⁵	5.79X10 ⁻²	3.49X10 ⁻⁷	na	na	1.26X10 ⁻⁶	5.71X10 ⁶	8.02X10 ⁻³	<3.00X10 ⁻⁹ ³

1 na - not applicable - Inhibited reaction rates were linear over the course of the reactions. $k_{off} > 0.5 \text{ min}^{-1}$.

2 nt - not tested.

3 Calculated IC₅₀ value was less than three times the enzyme concentration in the reaction (1 nM).

-22-

Materials and Methods used in Laboratory Example 3

Expression and purification: as described for Laboratory Example 1, except only wild type RT.

Biotinylated Template Prime (25:17mer): All buffers were made with 5 diethyl pyrocarbonate (DEPC)-treated water and autoclaved. Template primer was made in sterile RNase-free containers. 5'-biotinylated DNA primer, biotin-5'-GTC ATA GCT GTT TCC TG-3' (SEQ ID NO:2), and the RNA template, 5'-AUU UCA CAC AGG AAA CAG CUA UGA C-3' (SEQ ID NO:3), were custom synthesized by Oligos Etc., Wilsonville, Oregon. The 5'-biotinylated 17-mer 10 DNA primer (40 nmoles) was mixed with the 25-mer RNA template (20 nmoles) in 1 ml of 10 mM Tris-HCl, pH 8.0, 1 mM MgCl₂. The solution was divided into 9 x 111 µl samples, heated in a dry bath incubator (Fisher Scientific, Pittsburgh, Pennsylvania) at 92°C for 5 min., cooled to 40°C over 4 hrs, and stored at -20°C.

15 Substrate, Enzyme, and Test Compounds Solution Preparation: Substrate solution and diluted RT were prepared on the day of the assay. Substrate solution was maintained at 4°C. One microliter of test compounds (0.5 mM in DMSO) were dispensed in columns 1 through 20 of 384 well plates, and one microliter of DMSO was dispensed in column 21.

20 Reagents and Labware.

384 well plates: Costar 384 well assay plates, solid black, #3710

Assay buffer: 50 mM Tris-HCl pH 8.0, 80 mM KCl, 10 mM MgCl₂, 0.0032% NP40, 10 mM L-cysteine.

25 Biotinylated Template Prime (25:17 mer): as described for Laboratory Example 1 above.

Cy5-AP3-dUTP: as described in Laboratory Example 1 above.

RT: diluted to 1.25 nM in Assay Buffer.

Substrate Solutions: 100nM Cy5-dUTP, 20 nM Eu-labeled Streptavidin, 20 nM biotinylated template primer in Assay Buffer

30 Thymidine triphosphate (TTP): 9 micromolar
Tris Hydrochloride solution

-23-

Laboratory Example 3 – High Throughput RT Assay

RT Assay: Reactions contained 20 nM Cy5-dUTP, 4 nM Eu-labeled template primer, 1nM RT, 50 mM Tris-HCl, 80mM KCl, 10 mM MgCl₂, 0.0032% NP40, 10 mM L-Cysteine, 2% DMSO and 1nM RT. Stock substrate and TTP solutions were maintained at 4°C throughout the assay. RT was kept at ambient temperature. Using a BIOMEK® 2000, 10 µl of substrate solution were added to each well containing 1 µl test compound or DMSO. TTP (10 µl 9 µM) was added to wells I21-P21 prior to the start of the reaction to inhibit any Cy5-dUMP incorporation into the primer template. These wells served as background controls. Wells A21-H21 contained DMSO only and served as uninhibited controls. Serially diluted positive controls with known inhibitors were also included on separate wells. Columns 22-24 were empty on both test and control plates.

The RT reactions were initiated by the addition of 40 µl of dilute RT to each well using a MULTIDROP™ 384 (available from Titertek Instruments, Inc. of Huntsville, Alabama) and incubated at ambient temperature. The rate of Cy5-dUMP incorporation into the Eu-labeled template primer was determined by measuring time-resolved fluorescence at approximately 5 minutes and 40 minutes after enzyme addition with a VICTOR™ 1420 Multilabel Counter (Wallac, Gaithersburg, Maryland).

Laboratory Example 4 – Data Analysis for High Throughput Assay

The rate of Cy5dUMP incorporation was calculated by subtracting the time-resolved fluorescence measured 5 minutes after enzyme addition from the time-resolved fluorescence measured at 40 min and dividing by the time interval. The results for each test well in the primary screen were expressed as % inhibition (I) calculated according to the equation (4):

$$\%I = 1 - x (1 - (\text{rate}_{\text{sample}} / \text{rate}_{\text{control}}))$$

30

where $\text{rate}_{\text{sample}}$ is the Cy5dUMP incorporation rate in the presence of test compound, and $\text{rate}_{\text{control}}$ is the rate in the absence of any test compound.

-24-

The value for $rate_{control}$ was the average of the control wells included in every plate.

For the standard inhibitors, the % control activity (%C) at each concentration of standard inhibitor was calculated by the equation (5):

5

$$\%C = 100 \times (rate_{sample}/rate_{control})$$

IC₅₀ values for the inhibitors were determined by non-linear least square fit of the equation (6):

10

$$\%C = V_{max} \times (1 - (X/(IC_{50} + X)))$$

to the data, where %C is the activity observed at inhibitor concentration X and V_{max} is the rate in the absence of inhibitor (~100%).

15

IC₅₀ values and percent inhibition reported for NNRTIs are dependent on the template primer used and the time of incubation. Therefore, consistency in assay format is preferred. The rate calculation assumes incorporation is linear over a 35 minute time interval (5 and 40 minutes after enzyme addition) in the presence or absence of inhibitor. This is not the case 20 for slow-binding inhibitors. The IC₅₀ value for a slow-binding inhibitor determined by the 2 time-point method will therefore be higher than that determined by a full inhibition time-course analysis.

25

The application of which this description and claims form a part can be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application can be directed to any feature or combination of features described herein. They can take the form of product, composition, process or use claims and can include, by way of example and without limitation, one or more of the following claims.

30

It will be understood that various details of the invention can be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation--the invention being defined by the claims.

-25-

CLAIMS

What is claimed is:

1. A method of detecting polynucleic acid polymerase activity, the method comprising:

- 5 (a) providing a polynucleic acid primer-template complex labeled with an energy-emitting chemical species and a nucleotide labeled with an energy-emitting chemical species;
- (b) mixing the polynucleic acid primer-template complex and the nucleotide with a sample comprising or suspected to comprise a polynucleic acid polymerase;
- 10 (c) prior to, contemporaneously with or after the mixing of step (b), exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the energy-emitting chemical species to thereby excite that energy-emitting chemical species; and
- 15 (d) detecting a signal produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase, the detection of the signal indicating polynucleic acid polymerase activity in the sample.

2. The method of claim 1, wherein the nucleotide is selected from the group consisting of dUTP, dTTP, dATP, dCTP, dGTP, ATP, CTP, UTP, GTP and combinations thereof.

3. The method of claim 1, wherein the energy-emitting chemical species on the polynucleic acid primer-template complex is a donor chemical species and the energy-emitting chemical species on the nucleotide is an acceptor chemical species or wherein the energy-emitting chemical species on the nucleotide is a donor chemical species and the energy-emitting

chemical species on the polynucleic acid primer-template complex is an acceptor chemical species.

4. The method of claim 1, wherein the energy-emitting chemical
5 species on the polynucleic acid primer-template complex and the energy-emitting chemical species on the nucleotide are light-emitting chemical species.

5. The method of claim 4, wherein the light-emitting chemical
10 species are each selected from the group consisting of a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, and a bioluminescent compound.

6. The method of claim 5, wherein the fluorescent compound is
15 selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, Texas red, cascade blue, Oregon green, phycoerythrin, CY3, CY5, CY2, CY7, coumarin, infrared 40, MR 200 and IRD 40.

20

7. The method of claim 5, wherein the light-emitting chemical species on the polynucleic acid primer-template complex, the light-emitting chemical species on the nucleotide or both the light-emitting chemical species on the polynucleic acid primer-template complex and the light-emitting 25 chemical species on the nucleotide are rare earth metals.

8. The method of claim 7, wherein the rare earth metal light-emitting chemical species on the polynucleic acid primer-template complex, the rare earth metal light-emitting chemical species on the nucleotide or both 30 the rare earth metal light-emitting chemical species on the polynucleic acid primer-template complex and the rare earth metal light-emitting chemical species on the nucleotide are lanthanides.

-27-

9. The method of claim 8, wherein the lanthanide further comprises a lanthanide chelate.

10. The method of claim 9, wherein the lanthanide chelate further 5 comprises lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium or lutetium.

11. The method of claim 5, wherein the chemiluminescent 10 compound is selected from the group consisting of luminol, isoluminol, theromatic acridinium ester and acridinium salt.

12. The method of claim 5, wherein the bioluminescent compound is selected from the group consisting of luciferin, luciferase and aequorin.

15 13. The method of claim 1, wherein the polynucleic acid polymerase is a DNA polymerase or a RNA polymerase.

14. The method of claim 13, wherein the polymerase is a reverse 20 transcriptase.

15. The method of claim 1, further comprising detecting the signal at a plurality of time points over a predetermined time-period.

25 16. The method of claim 1, further comprising screening a plurality of samples simultaneously for polynucleic acid polymerase activity.

17. The method of claim 16, wherein steps (a) through (d) are carried out for each sample in a single well of a multi-well plate.

30 18. A method for identifying a candidate compound as a modulator of polynucleic acid polymerase activity, the method comprising:

-28-

- (a) providing a candidate compound, a polynucleic acid primer-template complex labeled with an energy-emitting chemical species and a nucleotide labeled with an energy-emitting chemical species;
- 5 (b) mixing the candidate compound, the polynucleic acid primer-template complex and the nucleotide with a polynucleic acid polymerase;
- (c) prior to, contemporaneously with or after the mixing of step (b), exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the energy-emitting chemical species to thereby excite that energy-emitting chemical species;
- 10 (d) detecting a signal produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase, the detected signal indicating an amount of polynucleic acid polymerase activity; and
- 15 (e) identifying the candidate compound as a modulator of polynucleic acid polymerase activity based on the amount of signal detected as compared to a control sample.

19. The method of claim 18, wherein the nucleotide is selected from the group consisting of dUTP, dTTP, dATP, dCTP, dGTP, ATP, CTP, UTP, GTP and combinations thereof.

20. The method of claim 18, wherein the energy-emitting chemical species on the polynucleic acid primer-template complex is a donor chemical species and the energy-emitting chemical species on the nucleotide is an acceptor chemical species or wherein the energy-emitting chemical species on the nucleotide is a donor chemical species and the energy-emitting

-29-

chemical species on the polynucleic acid primer-template complex is an acceptor chemical species.

21. The method of claim 18, wherein the energy-emitting chemical
5 species on the polynucleic acid primer-template complex and the energy-emitting chemical species on the nucleotide are light-emitting chemical species.

22. The method of claim 21, wherein the light-emitting chemical
10 species are each selected from the group consisting of a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, and a bioluminescent compound.

23. The method of claim 22, wherein the fluorescent compound is
15 selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, Texas red, cascade blue, Oregon green, phycoerythrin, CY3, CY5, CY2, CY7, coumarin, infrared 40, MR 200 and IRD 40.

20
24. The method of claim 22, wherein the light-emitting chemical species on the polynucleic acid primer-template complex, the light-emitting chemical species on the nucleotide or both the light-emitting chemical species on the polynucleic acid primer-template complex and the light-emitting chemical species on the nucleotide are rare earth metals.

25. The method of claim 24, wherein the rare earth metal light-emitting chemical species on the polynucleic acid primer-template complex, the rare earth metal light-emitting chemical species on the nucleotide or both the rare earth metal light-emitting chemical species on the polynucleic acid primer-template complex and the rare earth metal light-emitting chemical species on the nucleotide are lanthanides.

-30-

26. The method of claim 25, wherein the lanthanide further comprises a lanthanide chelate.

27. The method of claim 26, wherein the lanthanide complex further 5 comprises lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium or lutetium.

28. The method of claim 22, wherein the chemiluminescent 10 compound is selected from the group consisting of luminol, isoluminol, theromatic acridinium ester and acridinium salt.

29. The method of claim 22, wherein the bioluminescent compound is selected from the group consisting of luciferin, luciferase and aequorin.

15 30. The method of claim 18, wherein the polynucleic acid polymerase is a DNA polymerase or a RNA polymerase.

31. The method of claim 30, wherein the polymerase is a reverse 20 transcriptase.

32. The method of claim 18, further comprising detecting the signal at a plurality of time points over a predetermined time period.

25 33. The method of claim 32, further comprising calculating an association constant and a dissociation constant for the candidate compound for modulation of polynucleic acid polymerase activity.

30 34. The method of claim 32, further comprising calculating an IC_{50} value for the candidate compound for modulation of polynucleic acid polymerase activity.

-31-

35. The method of claim 18, further comprising screening a plurality of candidate compounds simultaneously for polynucleic acid polymerase modulator activity.

5 36. The method of claim 35, wherein steps (a) through (d) are carried out for each sample in a single well of a multi-well plate.

37. A method for identifying a candidate compound as a modulator of polynucleic acid polymerase activity, the method comprising:

- 10 (a) providing a candidate compound, a polynucleic acid primer-template complex labeled with a light-emitting chemical species and a nucleotide labeled with a light-emitting chemical species;
- (b) mixing the candidate compound, the polynucleic acid primer-template complex and the nucleotide with a polynucleic acid polymerase;
- 15 (c) prior to, contemporaneously with or after the mixing of step (b), exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the light-emitting chemical species to thereby excite that light-emitting chemical species;
- 20 (d) detecting a signal at a plurality of time points over a predetermined time period, the signal produced by energy transfer between the excited light-emitting chemical species and the other light-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase, the detected signal indicating an amount of polynucleic acid polymerase activity; and
- 25 (e) identifying the candidate compound as a modulator of polynucleic acid polymerase activity based on the amount of signal detected as compared to a control sample.

-32-

38. The method of claim 37, wherein the nucleotide is selected from the group consisting of dUTP, dTTP, dATP, dCTP, dGTP, ATP, CTP, UTP, GTP and combinations thereof.

5 39. The method of claim 37, wherein the light-emitting chemical species on the polynucleic acid primer-template complex is a donor chemical species and the light-emitting chemical species on the nucleotide is an acceptor chemical species or wherein the light-emitting chemical species on the nucleotide is a donor chemical species and the light-emitting chemical species on the polynucleic acid primer-template complex is an acceptor chemical species.

10 40. The method of claim 37, wherein the light-emitting chemical species are each selected from the group consisting of a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, and a bioluminescent compound.

15 41. The method of claim 40, wherein the fluorescent compound is selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, Texas red, cascade blue, Oregon green, phycoerythrin, CY3, CY5, CY2, CY7, coumarin, infrared 40, MR 200 and IRD 40.

20 42. The method of claim 40, wherein the light-emitting chemical species on the polynucleic acid primer-template complex, the light-emitting chemical species on the nucleotide or both the light-emitting chemical species on the polynucleic acid primer-template complex and the light-emitting chemical species on the nucleotide are rare earth metals.

25 43. The method of claim 42, wherein the rare earth metal light-emitting chemical species on the polynucleic acid primer-template complex, the rare earth metal light-emitting chemical species on the nucleotide or both the rare earth metal light-emitting chemical species on the nucleotide or both

-33-

the rare earth metal light-emitting chemical species on the polynucleic acid primer-template complex and the rare earth metal light-emitting chemical species on the nucleotide are lanthanides.

5 44. The method of claim 43, wherein the lanthanide further comprises a lanthanide chelate.

45. The method of claim 44, wherein the lanthanide comprises lanthanum, cerium, praseodymium, neodymium, promethium, samarium, 10 europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium or lutetium.

15 46. The method of claim 40, wherein the chemiluminescent compound is selected from the group consisting of luminol, isoluminol, theromatic acridinium ester and acridinium salt.

47. The method of claim 40, wherein the bioluminescent compound is selected from the group consisting of luciferin, luciferase and aequorin.

20 48. The method of claim 40, wherein the light-emitting chemical species is a lanthanide chelate and the light-emitting chemical species is a fluorescent dye.

49. The method of claim 37, wherein the polynucleic acid 25 polymerase is a DNA polymerase or a RNA polymerase.

50. The method of claim 49, wherein the polymerase is a reverse transcriptase.

30 51. The method of claim 37, further comprising calculating an association constant and a dissociation constant for the candidate compound for modulation of polynucleic acid polymerase activity.

-34-

52. The method of claim 37, further comprising calculating an IC₅₀ value for the candidate compound for modulation of polynucleic acid polymerase activity.

5 53. The method of claim 37, further comprising screening a plurality of candidate compounds simultaneously for polynucleic acid polymerase modulator activity.

10 54. The method of claim 53, wherein steps (a) through (d) are carried out for each sample in a single well of a multi-well plate.

-1-

SEQUENCE LISTING

<110> Roberts, Grace B.

Eric S. Furfine

5 David J. T. Porter

<120> CONTINUOUS TIME RESOLVED RESONANCE ENERGY
TRANSFER ASSAY FOR POLYNUCLEIC ACID POLYMERASE ACTIVITY

10 <130> Docket No. PU3761

<140>

<141>

15 <150> 60/167,940

<151> 1999-11-29

<160> 3

20 <170> PatentIn Ver. 2.1

<210> 1

<211> 537

<212> PRT

25 <213> Human immunodeficiency virus type 1

<220>

<223> Xaa at position 100 can be Leu or Ile

30 <220>

<223> Xaa at position 103 can be Lys or Asn

<220>

-2-

<223> Xaa at position 106 can be Val, Ile or Ala

<220>

<223> Xaa at position 108 can be Val or Ile

5

<220>

<223> Xaa at position 138 can be Glu or Lys

<220>

10 <223> Xaa at position 181 can be Tyr or Cys

<220>

<223> Xaa at position 188 can be Tyr or Cys

15 <220>

<223> Xaa at position 236 can be Pro or Leu

<400> 1

20 Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met

1

5

10

15

Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys

20

25

30

25

Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser

35

40

45

30

Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala Ile Lys

50

55

60

Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu

-3-

	65	70	75	80
	Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His			
	85	90		95
5				
	Pro Ala Gly Xaa Lys Lys Xaa Lys Ser Xaa Thr Xaa Leu Asp Val Gly			
	100	105		110
	Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr			
10	115	120		125
	Ala Phe Thr Ile Pro Ser Ile Asn Asn Xaa Thr Pro Gly Ile Arg Tyr			
	130	135		140
15	Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe			
	145	150	155	160
	Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro			
	165	170		175
20				
	Asp Ile Val Ile Xaa Gln Tyr Met Asp Asp Leu Xaa Val Glys Ser Asp			
	180	185		190
	Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His			
25	195	200		205
	Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu			
	210	215	220	
30	Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Xaa Asp Lys Trp Thr			
	225	230	235	240

-4-

Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp
245 250 255

5 Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Pro
260 265 270

Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala
275 280 285

10 Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala
290 295 300

Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp
15 305 310 315 320

Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gln
325 330 335

20 Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly
340 345 350

Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu
355 360 365

25 Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly
370 375 380

Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr
30 385 390 395 400

-5-

Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe
405 410 415

Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu
5 420 425 430

Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg
435 440 445

10 Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln
450 455 460

Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln
15 465 470 475 480

Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val
485 490 495

20 Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Gln
500 505 510

Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys
515 520 525

25 Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly
530 535 540

Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu
30 545 550 555 560

<210> 2

<211> 17

<212> DNA

5 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthesized
oligonucleotide

10

<400> 2

gtcatagctg tttcctg

17

<210> 3

15 <211> 25

<212> RNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: synthesized
oligonucleotide

<400> 3

auuucacaca ggaaacagcu augac

25

25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number
WO 01/38587 A3

(51) International Patent Classification⁷: C12Q 1/48 (74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 et al. (US).

(21) International Application Number: PCT/US00/32536

(22) International Filing Date: 29 November 2000 (29.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/167,940 29 November 1999 (29.11.1999) US

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FURFINE, Eric, Steven [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). PORTER, David, John, Timothy [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). ROBERTS, Grace, Brashears [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report: 10 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A3

(54) Title: ENERGY-TRANSFER ASSAY FOR POLYNUCLEIC ACID POLYMERASES

(57) Abstract: A method of detecting polynucleic acid polymerase activity, including DNA and RNA polymerase activity. The method includes providing a polynucleic acid primer-template complex labeled with a energy-emitting chemical species and a nucleotide labeled with a energy-emitting chemical species; mixing the polynucleic acid primer-template complex and the nucleotide with a sample comprising or suspected to comprise a polynucleic acid polymerase; prior to, contemporaneously with or after the mixing, exposing the labeled polynucleic acid primer-template complex and the labeled nucleotide to radiation of excitation wavelength for one of the energy-emitting chemical species to thereby excite that energy-emitting chemical species; and detecting a signal produced by energy transfer between the excited energy-emitting chemical species and the other energy-emitting chemical species as a result of incorporation of the nucleotide into the polynucleic acid primer-template complex via the activity of the polynucleic acid polymerase, the detection of the signal indicating polynucleic acid polymerase activity in the sample. Candidate compounds can also be identified as modulators of polynucleic acid polymerase activity via the method.

WO 01/38587

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/32536

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BEATRICE ALPHA-BAZIN ET AL: "New homogeneous reverse transcriptase and nuclease assays based on rare earth cryptate and fluorescent energy transfer." NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 6-7, June 1999 (1999-06), pages 1277-1278, XP001010024 ISSN: 0732-8311 page 1278, line 11 - line 26 ---</p> <p style="text-align: center;">-/-</p>	1-54

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 June 2001

Date of mailing of the International search report

11/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/32536

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	ZHANG JI-HU ET AL: "A high-throughput homogeneous assay for reverse transcriptase using generic reagents and time-resolved fluorescence detection." ANALYTICAL BIOCHEMISTRY, vol. 281, no. 2, 1 June 2000 (2000-06-01), pages 182-186, XP002170816 ISSN: 0003-2697 page 184; figure 1 ---	1-54
A	EP 0 443 823 A (EASTMAN KODAK CO ; CETUS CORP (US)) 28 August 1991 (1991-08-28) claims 1,8-14 ---	1-54
T	WO 01 27318 A (QUIP TECHNOLOGY LTD ; DOHERTY IAIN (GB); LOVATT ARCHIBALD (GB); SMI) 19 April 2001 (2001-04-19) claims 1-13 ---	1-54
P,A	US 6 100 039 A (BURKE THOMAS J ET AL) 8 August 2000 (2000-08-08) claim 1; figure 1 ---	1-54

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 00/32536

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0443823	A 28-08-1991	US 5049490	A	17-09-1991
		AT 130045	T	15-11-1995
		CA 2036714	A	21-08-1991
		DE 69114325	D	14-12-1995
		DE 69114325	T	18-07-1996
		DK 443823	T	11-12-1995
		FI 910822	A	21-08-1991
		IE 910559	A	28-08-1991
		JP 6062898	A	08-03-1994
WO 0127318	A 19-04-2001	NONE		
US 6100039	A 08-08-2000	NONE		